| Literature DB >> 34188964 |
Syuichi Tetsuka1, Tomohiro Suzuki1, Tomoko Ogawa1, Ritsuo Hashimoto1, Hiroyuki Kato1.
Abstract
Primary cytomegalovirus (CMV) infection in healthy young adults is usually an asymptomatic or mononucleosis-like syndrome, whereas in immunocompromised patients, CMV can cause significant disease. In this study, we report an unusual case of primary CMV infection wherein the patient, an immunocompetent 21-year-old woman, presented severe encephalopathy, acute hepatitis, retinitis, and reactivation of latent Epstein-Barr virus. She developed confusion, high fever, headache, and tonic-clonic seizures. Brain magnetic resonance imaging showed high-intensity lesions in the medial temporal lobe and basal ganglia. Liver dysfunction was observed, and abdominal computed tomography revealed splenohepatomegaly. After fundus findings, the patient was diagnosed with CMV retinitis. Upon admission, she was treated with intravenous acyclovir and steroid pulse therapy. Considering both her serious clinical condition and elevated serum levels of interleukin-6, we speculated that her condition was similar to cytokine-storm-induced encephalopathy. On day 2 after admission, she showed prompt recovery from these clinical manifestations. Since blood CMV pp65 antigenemia was found to be positive, we administered ganciclovir for 2 weeks. On the basis of her clinical manifestations and the presence of blood CMV DNA and CMV pp65 antigenemia along with IgM kinetics, we finally diagnosed this patient with severe primary CMV infection. She left our hospital without sequelae 20 days after admission. The incidence of severe CMV disease in immunocompetent young adults might be higher than previously recognized. Noninvasive testing for CMV (such as CMV pp65 antigenemia and CMV DNAemia) is widely available and can help early diagnosis. Short-term glucocorticoid therapy might be beneficial in the treatment of encephalopathy in the early stages of primary CMV infection. Considering such a background, clinicians should keep severe primary CMV infection in mind as a differential diagnosis in the clinical setting.Entities:
Year: 2021 PMID: 34188964 PMCID: PMC8195643 DOI: 10.1155/2021/5589739
Source DB: PubMed Journal: Case Rep Infect Dis
Laboratory investigations
| Investigations | Result on admission | Results two weeks after the admission | Results four months after the admission |
|---|---|---|---|
| WBC (/ | 11530 | 7600 | 6800 |
| Differential count (%) | N 47.0, L 27.0, M 3.0, A 23.0 | N 68.0, L 25.4, M 6.6, A 0 | N 60.5, L 34.9, M 4.6, A 0 |
| Hemoglobin (g/dl), (11.2–15.2) | 12.4 | 12.2 | 12.5 |
| Platelet count (×109/L), (14.9–37.9) | 22.2 | 30.3 | 23.1 |
| CRP (mg/dl), (<0.3) | 3.34 | 0.04 | 0.04 |
| HBV, HCV serology | Negative | ||
| Serum HIV antibody | Negative | Negative | |
| Blood HIV RNA | Negative | ||
| AST (U/l), (8–38) | 116 | 20 | 21 |
| ALT (U/l), (4–44) | 183 | 22 | 16 |
| Glucose (mg/dl), (70–109) | 140 | 158 | 93 |
| CSF counts (cells/mm3) | WBC 186 (N 6, L 180) | WBC 21 (N 0, L 21) | |
| CSF glucose (mg/dl), (50–75) | 96 | 58 | |
| CSF protein (mg/dl), (15–45) | 41 | 37 | |
| CSF gram stain and culture | Negative | ||
| CSF TB-PCR | Negative | ||
| CSF fungal culture | Negative | ||
| Nasopharynx influenza antigen (A and B) | Negative | ||
| Nasopharynx COVID-19 RNA | Negative | ||
| Blood CMV pp65 antigenemia (0 pp65-positive cells per 5 × 105 cells) | Positive (17) | Negative (0) | Negative (0) |
| Blood CMV DNA | Positive (1.6 × 103 copies/ml) | Negative | |
| CSF CMV DNA | Negative | ||
| Serum anti-CMV IgM (<0.8 titers) | Positive (8.54) | Positive (7.49) | Positive (2.99) |
| Serum anti-CMV IgG (<2.0 titers) | Positive (15.5) | Positive (71.0) | Positive (42.5) |
| CSF HSV DNA | Negative | ||
| Serum anti-HSV IgM (<0.8 titers) | Negative (0.28) | ||
| Serum anti-HSV IgG (<2.0 titers) | Negative (<2.0) | ||
| Blood EBV DNA | Positive (2.93 log IU/ml) | Negative | |
| CSF EBV DNA | Negative | ||
| Serum anti-EBNA IgG (<0.5 titers) | Positive (4.0) | Positive (3.1) | Positive (4.3) |
| Serum anti-VCA-IgM (<0.5 titers) | Positive (12.7) | Positive (8.9) | Positive (1.4) |
| Serum anti-VCA-IgG (<0.5 titers) | Positive (8.2) | Positive (8.3) | Positive (8.4) |
| Serum anti-VZV IgM (<0.8 titers) | Positive (1.32) | Positive (1.48) | Negative (0.62) |
| Serum anti-VZV IgG (<2.0 titers) | Positive (89.0) | Positive (74.0) | Positive (55.6) |
| Serum antimumps IgM (<0.8 titers) | Positive (2.9) | Positive (2.58) | Borderline (0.82) |
| Serum antimumps IgG (<2.0 titers) | Positive (47.0) | Positive (39.0) | Positive (23.5) |
| Serum interleukin-6 (pg/ml), (<4) | 10.3 | 2.4 |
Normal ranges are given in parentheses. WBC, white blood cell; N, neutrophils; L, lymphocytes; M, monocytes; A, atypical lymphocytes; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; CSF, cerebrospinal fluid; TB, tuberculosis; PCR, polymerase chain reaction; CMV, cytomegalovirus; HSV, herpes simplex virus; EBV, Epstein–Barr virus; EBNA, Epstein–Barr virus nuclear antigen; VCA, virus capsid antigen; VZV, varicella-zoster virus; IgM, immunoglobulin M; IgG, immunoglobulin G.
Figure 1Abdominal contrast-enhanced CT upon admission. (a) Axial view; (b) Coronal view. There is splenohepatomegaly.
Figure 2Brain MRI studies at the onset. Axial view of fluid-attenuated inversion recovery (FLAIR) images showing high-intensity lesions in the left medial temporal lobe (a), bilateral caudate nucleus, and left lentiform nucleus (b). (c), (d) MRI studies on the second day of follow-up. FLAIR images show a normal signal in the medial temporal lobe and basal ganglia and no abnormal lesion. Arrowheads indicate high-intensity lesions.
Figure 3Fundus appearance on admission. There is white punctate exudate around the macula (a) and petechiae were observed (b) in the retina of the left eye. Arrowheads indicate petechiae.